CounterVail Corporation

May, 2007
Final Market Opportunity Analysis Completed
Technical Due Diligence Completed
Initial Discussion with World Health Organization
Initial Discussion with Pan-American Health Organization
Initial Discussion with BARDA
Patent submissions in 25 Countries finalized and filed
June, 2007
Corporate Counsel Engaged
Countervail Incorporated
Corporate Governance Documents Completed
Master Licensing Agreement Negotiated with University of Maryland Baltimore
July, 2007
Patent Counsel Engaged
Master License Agreement Signed with University of Maryland Baltimore
PHEMCE Participation (Public Health Emergency Medical Countermeasures Enterprise)
August, 2007
BARDA Industry Day Participation and Presentation
(Biomedical Advanced Research and Development Authority)
Initial Seed Financing secured
BARDA Committee Presentation
ARMY Presentation
September, 2007
FDA Consultant Engaged
NIH Presentation
UMB Update Completed
October, 2007
Pre-, Pre-IND Committee Discussion and Presentation (FDA, NIH , DOD and BARDA)
November, 2007
First Round Meetings with potential Contract Manufacturing Organizations
BARDA Committee Update
December, 2007
Initial Discussions with Contract Research Laboratories for GLP Studies
UMB Update
January, 2008
Meetings with Contract Research Laboratories for GLP Studies
February, 2008
Meetings with DTRA (Defense Threat Reduction Agency)
March, 2008
Meetings and Presentation with NINDS
(National Institute of Neurological Disorders and Stroke)
Presentation at New Jersey Economic Development Council
Presentation at New Jersey Technical Council
UMB Update Meeting
April, 2008
Meetings and Presentation at 2nd Annual CounterACT Network Research Symposium
(Countermeasures against Chemical Threats)
Meetings and Presentation at North Carolina Venture Capital Symposium
May, 2008
Scheduled Presentation at New Jersey Bio-Terrorism Conference
June, 2008
Countervail Corporation awarded $ 25,000 in matching business development funding from the NC BioTech Center in support of FDA Pre-IND activities for product commercialization.

Chemical Threats

Pesticide Poisoning

Use of volatile nerve gas agents by terrorist organizations is a key concern of the US Homeland Security Department. Congress has passed the Project Bioshield Act that authorized $5.6 billion for use in procuring terrorist medical countermeasures which includes nerve gas agents. None of the currently available antidotes protect the brain from these toxins and have numerous other drawbacks. As an example, the current anti-nerve gas agent used by the military cannot be taken at the time of a nerve gas attack to protect troops and has been implicated as a cause of the Gulf War Syndrome. The active substances in most nerve gas agents (Soman, Sarin) and in pesticides are organophosphates (OP) which cause severe damage to the nervous system by irreversibly binding to acetylcholinesterase.

Nerve Gas Agents

There are currently over 21 million US military and support personnel of which more than 9.8 million are considered to be at risk for either primary or secondary exposure from nerve gas attacks.

NATO has over 9 million military and support personnel of which more than 4 million are considered to be at risk for either primary or secondary exposure from nerve gas attacks.

Currently, military and civilian support personnel in the immediate danger zone are supplied with auto-injectors containing a variety of chemical agents to be used in case of a nerve-gas attack. These are bulky, have a relatively short shelf life in field conditions, are painful to the recipient, must be administered in a certain order to be effective and carry the risk of inadvertent injection of products in the absence of exposure. In addition, First Responders must be provided with these products as well.

There are two primary Civilian populations at risk from a terrorist attack and may also be exposed to these nerve gas agents. These include civilian populations in high density municipal targets of interest as well as Primary First Responders which are comprised of EMT and ER Personnel. There are over 2,000 hospitals and clinics within these primary areas. It is recommended that the facilities within a projected area of attack should be prepared to handle between 15,000 and 20,000 casualties from the initial exposure.

Agricultural

Pesticide use in Developing Countries has been steadily rising since 2004. Many of the products sold in these countries are older, cheaper pesticides (most organophosphate based) which are more persistent in the environment and more hazardous to the health of the user. In areas of persistent pesticide use, the environment is deteriorating resulting in contaminated water supplies, loss of plant diversity, increased insect resistance and cattle / other domestic animal deaths.

According to the World Health Organization (WHO) and the Pan American Health Organization (PAHO), there were approximately 1.8 billion agricultural workers in developing countries in 2005. Some estimates indicate there are between 39 million and 50 million episodes of acute pesticide poisoning annually with deaths of up to 10% within some geographical areas.